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Abstract: In this work, we report that the biodistribution and excretion of carbon nanohorns 
(CNHs) in mice are dependent on their size and functionalization. Small-sized CNHs (30–50 nm; 
S-CNHs) and large-sized CNHs (80–100 nm; L-CNHs) were chemically functionalized and 
radiolabeled with [111In]-diethylenetriaminepentaacetic acid and intravenously injected into 
mice. Their tissue distribution profiles at different time points were determined by single photon 
emission computed tomography/computed tomography. The results showed that the S-CNHs 
circulated longer in blood, while the L-CNHs accumulated faster in major organs like the liver 
and spleen. Small amounts of S-CNHs- and L-CNHs were excreted in urine within the first few 
hours postinjection, followed by excretion of smaller quantities within the next 48 hours in both 
urine and feces. The kinetics of excretion for S-CNHs were more rapid than for L-CNHs. Both 
S-CNH and L-CNH material accumulated mainly in the liver and spleen; however, S-CNH 
accumulation in the spleen was more prominent than in the liver.
Keywords: biodistribution, excretion, functionalization, nano-carbon, nanomedicine
Introduction
Carbon nanomaterials such as carbon nanotubes (CNTs),1–2 carbon nanohorns (CNHs),3 
and graphene-related materials4,5 have attracted tremendous interest in the past decade 
due to their unique physicochemical properties. Carbon nanomaterials can find poten-
tial applications in various fields, including medical imaging and therapeutics.5–11 
Their large available surface area, nanoscale dimensions, and possibility of multiple 
surface functionalization strategies make them unique materials with a lot of promise 
for the design of drug delivery systems.12–22 In addition, they offer high conversion 
efficiency of near-infrared radiation energy into heat, which enables them to be agents 
for photothermal therapy.22–24 Determination of the long-term fate of these carbon 
nanomaterials after administration into a living body is crucially important to allow 
the possibility for clinical translation.
To date, intensive efforts have been devoted toward assessment of safety issues 
related to carbon nanomaterials. In particular, several investigations aimed to evaluate the 
biodistribution of various functionalized CNTs and any potential adverse reaction.25–31 
Some of us previously reported that the surface functionalization of multiwalled CNTs 
determines the tissue distribution and excretion profile after intravenous administra-
tion.29 The modifications with polyethylene glycol (PEG) or PEG-derived polymers 
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have been reported to significantly extend blood circulation 
time of CNTs, reducing the risk of organ accumulation.25–26 
Adequately functionalized multiwalled CNTs radiolabeled 
with [111In] are retained in the reticuloendothelial system 
organs, such as the liver and spleen, but are also rapidly 
cleared from systemic blood circulation through the renal 
excretion route.27,28 The influence of type and degree of 
functionalization on the fate of injected CNTs has also been 
evaluated.29 However, the effect of other structural parameters 
like the particle size (ie, short versus long) and shape (ie, 
small versus large diameter) has not been fully understood. 
The main reason is likely due to the difficulties of obtaining 
uniform different-sized CNTs in large quantities.
CNHs are considered good candidates for drug carriers due 
to the fact that they have a large surface area (1,464 m2/g) but 
also a wide inner-tube and inter-tube space in each individual 
horn (0.69 mL/g) after hole-opening.32 Another advantage is 
that the CNHs are produced without catalysts3 and therefore 
they are devoid of any toxic risks associated with residual 
metallic impurities. Recent studies have also shown that 
CNHs can be separated into different controlled sizes,33,34 and 
small-sized CNHs (S-CNHs) with uniform sizes ~20–50 nm 
can be easily obtained in large quantity by an oxidative dis-
aggregation method.34 S-CNHs are highly hydrophilic and 
remarkably resistant to cellular uptake by macrophages.34 
Histological observations following intravenous administra-
tion have shown that S-CNHs accumulate in the liver and 
spleen more slowly than large-sized CNHs (L-CNHs) of 
80–120 nm in diameter.35 This suggested that the biodistribu-
tion of CNHs may be size-dependent and it can eventually be 
further controlled by chemical functionalization.
To quantitatively and dynamically study the biodis-
tribution of CNHs in vivo, we previously used Gd
2
O
3
 as 
label.36,37 Unfortunately, this type of labeling is based on 
annealing processes at high temperature resulting in S-CNH 
reaggregation into larger nanoparticles. To further analyze 
the fate of CNHs of different sizes and to perform a more 
detailed quantitative investigation, we utilized radioactive 
indium in this study (In-111) to label CNHs and to follow their 
tissue distribution and whole-body excretion after intravenous 
administration. For this purpose, the labeling process was per-
formed by an amidation reaction of oxidized CNHs with the 
chelating agent diethylenetriaminepentaacetic acid (DTPA), 
an approach that has been successfully used to investigate the 
pharmacokinetic profiles of CNTs.27–29 By using this func-
tionalization strategy, we can directly visualize the dynamic 
distribution of CNHs in whole body using single-photon emis-
sion computed tomography/computed tomography (SPECT/
CT) and quantitatively calculate the organ distribution using 
gamma scintigraphy. The data allowed comparison of the 
differences between S-CNHs and L-CNHs in organ accumula-
tion as well as in their excretion profiles.
Experimental
Materials
CNHs were synthesized by CO
2
 laser ablation of graphite 
at room temperature in Ar gas without a metal catalyst.3 
S- and L-CNHs were prepared by oxidation as described in 
the following sections.
s-cNhs
Pristine CNHs (40 mg) were dispersed in 30 mL H
2
SO
4
 
(98%; Wako Pure Chemical Industries, Ltd., Osaka, Japan) 
and stirred for 4 hours at room temperature.34 After cooling 
the suspension at 5°C, 10 mL HNO
3
 solution (67%; Wako 
Pure Chemical Industries, Ltd.) was slowly added, followed 
by sonication for 4 hours in a bath-type sonicator (~100 W) 
at 20°C. After sonication, the suspension was filtered (mem-
brane filter, pore size 0.2 µm), the S-CNHs on the filtration 
paper were washed with water and re-dispersed in water. The 
filtration and re-dispersion in water was repeated until the pH 
of the filtrate became neutral. The obtained S-CNHs were re-
dispersed in water (100 mL), sonicated at approximately 20°C 
with a tip-type sonicator (~300 W) for 30 minutes, and centri-
fuged at 10,000 rpm for 30 minutes. S-CNHs were collected 
from the upper 80% of supernatant. The concentration of the 
S-CNHs in the suspension was estimated from the absorbance 
at 700 nm measured with a ultraviolet-visible-near-infrared 
radiation spectrometer (Lambda 19; PerkinElmer Inc., 
Waltham, MA, USA). From the volume of the supernatant 
(~80 mL) and the concentration of S-CNHs (~0.1 mg/mL), the 
yield of S-CNHs was estimated to be ~20%. The size of the 
S-CNHs was estimated by dynamic light scattering (FPAR-
1000; Otsuka Electronic Co., Ltd., Osaka, Japan). To observe 
the morphologies of S-CNHs using transmission electron 
microscopy (TEM) (120 kV, 36 µA; 002B HRTEM; Topcon 
Corporation, Tokyo, Japan), one drop of S-CNH dispersion 
was placed on a Cu grid with ultrathin carbon film and dried 
at room temperature. Thermogravimetric analysis (TGA) of 
as-grown CNHs was performed in He using a TGA Q500 
(TA Instruments, New Castle, USA) with a heating rate of 
10°C⋅min-1, while the other analyses were done using a TGA1 
(Mettler Toledo, Schwerzenbach, Switzerland) apparatus 
from 30°C to 900°C with a ramp of 10°C⋅min-1 under N
2
 
using a flow rate of 50 mL⋅min-1 and platinum pans.
l-cNhs
The pristine CNHs were treated by light-assisted oxidation38 
to render them hydrophilic by generating oxygenated groups 
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such as carboxylic groups. Briefly, pristine CNHs (40 mg) 
were dispersed in an aqueous solution of H
2
O
2
 (30%, 60 mL) 
and heated at 70°C–80°C for 2 hours under irradiation using 
an Xe lamp. The resultant dispersion was filtered (membrane 
filter, pore size 0.2 µm), and the L-CNHs on the filter paper 
were washed and re-dispersed in water. The washing and re-
dispersion were repeated four times. The obtained L-CNHs 
were re-dispersed in water (100 mL) by sonication in a water 
bath for 5 minutes. Their characteristics were similarly exam-
ined using the techniques described earlier. Cu grids with holey 
carbon were used for TEM observation of L-CNHs.
chemical functionalization and labeling 
with 111In
L-CNHs or S-CNHs were first treated with an amino-DTPA 
derivative39 (see “Supplementary materials” for description 
of the synthesis of amino-DTPA, Figure S1) to allow chela-
tion of 111In (Figure 1). For this purpose, the CNHs (2.8 mg) 
were dispersed in oxalyl chloride (10 mL) using a water bath 
sonicator 20 W, 40 kHz  (Transsonics Digitals Elma, Singen, 
Germany). The suspension was heated at reflux for 16 hours. 
After evaporation of excess oxalyl chloride under reduced 
pressure, the CNHs were dispersed in anhydrous tetrahydro-
furan (THF) (1.9 mL) using water bath sonication. A solution 
of amino-DTPA (28 mg) and N,N-diisopropylethylamine 
(50 µL) in anhydrous dimethylformamide (DMF) (2.8 mL) 
was added. The suspension was sonicated in a water bath for 
2 minutes and then heated at 65°C for 2 days. After cooling to 
room temperature, the solvents were evaporated under reduced 
pressure. Ammonium acetate buffer (0.2 M, pH 5.5, 30 mL) 
was added to the residue. The suspension was dispersed 
using water bath sonication and centrifuged at 4,500 rpm for 
10 minutes. The supernatant was discarded and the precipitate 
was redispersed in ammonium acetate buffer. This sequence 
was repeated five times with ammonium acetate buffer and 
three times with deionized water. The precipitate was dis-
persed in deionized water using water bath sonication and the 
suspension was dialyzed in deionized water using 12–14 kDa 
molecular weight cut off (MWCO) dialysis membrane (Spec-
trum Laboratories, Inc., CA, USA) for 2 days.
For radiolabeling of the DTPA-S-CNHs or DTPA-L-
CNHs, equal volumes of 0.2 mg/mL solutions in water 
of each was mixed with 0.2 M ammonium acetate buffer 
(pH 5.5) to which 2–20 MBq of [111In]Cl
3
 was added. The 
indium was left to react with the DTPA-S-CNHs or DTPA-L-
CNHs for 30 minutes at room temperature. The excess 111In 
was treated with ethylenediaminetetraacetic acid (EDTA) 
(0.1 M) and removed by centrifugation (13,000 rpm for 
30 minutes). To determine the labeling efficiency, aliquots 
of each final product were diluted five times in phosphate-
buffered saline (PBS), and then 1 µL of the sample was 
spotted on silica gel impregnated glass fiber sheets (Pall 
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Figure 1 synthesis of [111In]DTPa-cNhs (s-cNhs or l-cNhs).
Note: Inset: structure of [111In]DTPa derivative used as control.
Abbreviations: DTPa, diethylenetriaminepentaacetic acid; cNhs, carbon nanohorns; s-cNhs, small-sized cNhs; l-cNhs, large-sized cNhs; DIea, N,N-diisopropyl-
ethylamine; DMF, dimethylformamide; ThF, tetrahydrofuran.
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Corporation, Port Washington, NY, USA). The strips were 
developed with a mobile phase of 50 mM EDTA in 0.1 M 
ammonium acetate and allowed to dry. They were then devel-
oped for the quantitative counting of radioactivity using a 
Cyclone phosphor detector (PerkinElmer Inc., Waltham, MA, 
USA). The immobile spot on the thin-layer chromatography 
strips indicated the percentage of radiolabeled [111In]DTPA-
S-CNH or [111In]DTPA-L-CNH conjugates, while [111In]
EDTA or [111In]DTPA corresponds to the migrated spots. 
After centrifugation, the pellets of [111In]DTPA-S-CNHs or 
[111In]DTPA-L-CNHs were resuspended in 5% dextrose. The 
final concentrations of CNHs were adjusted to 0.2 mg/mL. 
For evaluating the radiolabeling stability of [111In]DTPA-S-
CNHs or [111In]DTPA-L-CNHs, aliquots of each final product 
were diluted fivefold either in PBS or mouse serum and then 
incubated at 37°C over 24 hours. At different time points 
(0, 1, and 24 hours), 1 µL of the aliquots was spotted on 
silica gel impregnated glass fiber sheets and then developed, 
and quantified as described earlier. A control sample [111In]
DTPA was prepared by chelation of an acetylated DTPA 
ligand39 with [111In] (Figure 1, inset).
In vivo experiments
All animal procedures were performed in compliance with 
the UK Home Office Code of Practice for the Housing and 
Care of Animals used in Scientific Procedures. They were 
conducted following approval by the Institutional Ethical 
Review Committee, according to the UKCCCR Guidelines 
(1998) and under Project License 70/7763 granted by the UK 
Home Office. Six to 8-week-old C57/BL/6 mice (15–20 g), 
were purchased from Harlan (Oxfordshire, UK). Mice were 
housed in groups of five with free access to water and kept 
at a temperature of 19°C–22°C and relative humidity of 
45%–65%. Prior to performing the experiments, all animals 
were allowed to acclimatize for at least 7 days. The radiola-
beled S-CNHs or L-CNHs (50 µg, 3–5 MBq) were injected 
via the tail vein of mice after anesthetization by isoflurane 
inhalation. Immediately after injection (t=0.5 hours) and at 
t=3.5 hours, t=24 hours, and t=48 hours, mice were imaged 
using the Nano-SPECT/CT scanner (Bioscan, Washington, 
D.C., USA). CT scans were performed at the beginning of 
each SPECT acquisition. SPECT images were obtained in 
24 projections over 40–60 minutes using a four-head scanner 
with 1.4 mm pinhole collimators. All images were recon-
structed with MEDISO software (Medical Imaging Systems, 
Budapest, Hungary). Fusion of SPECT and CT images was 
carried out using the PMOD software (PMOD Technolo-
gies, Zurich, Switzerland). For quantitative assessment of 
tissue distribution of [111In]DTPA-S-CNHs or [111In]DTPA-
L-CNHs, mice were injected via the tail vein with 250 µL 
containing 50 µg of [111In]DTPA-S-CNHs or [111In]DTPA-
L-CNHs labeled with approximately 0.5–2 MBq. Mice 
were then sacrificed at 1, 4, and 24 hours after injection, 
and blood and all major organs and tissues were collected, 
including: heart, lungs, liver, spleen, kidneys, muscle, skin, 
and bone. Urine and feces were pooled and collected after 
24 hours. Each sample was weighed and counted on a gamma 
Counter (PerkinElmer Inc.), together with a dilution of the 
injected dose with dead time limit below 60%. The percent-
age injected dose per gram tissue was calculated, using four 
different mice for each time point.
Results and discussion
characterization of s-cNhs and 
l-cNhs, and their 111In labeling
The morphologies of S-CNHs and L-CNHs were shown in 
Figure 2A and 2B, respectively. S-CNHs contained indi-
vidual nanohorns and small-sized aggregates (Figure 2A), 
and their size was between 30 and 50 nm as estimated from 
dynamic light scattering (Figure 2C), in agreement with pre-
vious results.34 L-CNHs maintain the original spherical form 
of aggregates (Figure 2B) with size range of ~80–120 nm 
(Figure 2C). TGA of as-grown CNHs, L-CNHs, and S-CNHs 
performed in an inert atmosphere is shown in Figure 2D. 
The weight loss observed for L-CNHs and S-CNHs is 
mainly caused by the emission of CO and CO
2
 as a result 
of the thermal decomposition of oxygenated groups.40 The 
concentration of carboxyl groups in the buffer solutions 
was estimated to be 6 µmol for S-CNHs and 2.5 µmol for 
L-CNHs per milligram of material, taking into account the 
quantities of carboxyl groups assessed from the weight loss 
at 400°C, which is due to the decomposition of carboxyl 
groups.40 The COOH functions of both L-CNHs and S-CNHs 
were derivatized by amidation with the amino-DTPA deriva-
tive, via pre-activation of the carboxyl groups using oxalyl 
chloride. TGA performed in an inert atmosphere confirmed 
the successful functionalization of L-CNHs and S-CNHs 
with DTPA (Figure 2D). Indeed, the weight loss of DTPA-
L-CNHs and DTPA-S-CNHs was higher compared to the 
L-CNHs and S-CNHs, respectively.
DTPA-amidated S-CNHs and L-CNHs were then 
labeled with 111In, and the labeling efficiencies directly 
after the radiolabeling reaction corresponded to 64.6% 
and 95.2%, respectively (Figure S2). None or very little 
traces of free [111In]DTPA molecules were confirmed by 
thin-layer chromatography before injecting the material in 
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Figure 2 characteristics of s-cNhs and l-cNhs.
Notes: (A and B) TeM images of s-cNhs and l-cNhs, respectively. (C) Dynamic light scattering results of s-cNhs and l-cNhs dispersed in water. (D) Tga of as-grown 
cNhs (black), l-cNhs (red), s-cNhs (green), DTPa-l-cNhs (blue), and DTPa-s-cNhs (cyan).
Abbreviations: DTPa, diethylenetriaminepentaacetic acid; cNhs, carbon nanohorns; s-cNhs, small-sized cNhs; l-cNhs, large-sized cNhs; TeM, transmission electron 
microscopy; Tga, thermogravimetric analysis.
mice. The 111In atoms were not released from the chelating 
function in PBS or in serum at 37°C for 24 hours (Figures S3 
and S4).
cNh tissue distribution
Three-dimensional SPECT/CT reconstruction images of 
mice whole-bodies after injection of [111In]DTPA-S-CNHs, 
[111In]DTPA-L-CNHs, and [111In]DTPA are shown in 
Figures 3 and S5. The quantities are indicated with colors. 
[111In]DTPA-S-CNHs or [111In]DTPA-L-CNHs accumulated 
mainly in the liver and spleen. They were also observed in the 
kidney or bladder at early time points. After 24 hours and 48 
hours postinjection, the signals were still persistent only in the 
liver and spleen. SPECT/CT images of S-CNHs showed rela-
tively weaker signal intensities than those of L-CNHs because 
of the relatively lower labeling efficiency (Figure S2). Signals 
in the bladder of [111In]DTPA-L-CNHs remained even after 
4 hours compared to [111In]DTPA-S-CNHs. The control 
sample [111In]DTPA was almost completely excreted within 
the first hour (Figure S5).
Gamma scintigraphy was then used for the quantification 
of S-CNHs and L-CNHs in blood and the major organs and 
tissues like skin, liver, spleen, kidney, heart, lung, muscle, 
bone, stomach, and intestine at different time points (ie, 1, 
4, and 24 hours) (Figure 4 and Table 1). The control sample 
[111In]DTPA was used for comparison (Figure S6 and 
Table 1). Both types of CNH signals in blood reduced rap-
idly within the first hour. However, low levels of the smaller 
[111In]DTPA-S-CNHs remained constantly circulating in 
blood, with 2.5 µg/mL (1.3% injected dose [ID]) remaining 
in blood after 24 hours. Levels of the larger [111In]DTPA-L-
CNHs reduced more rapidly in blood and only 0.82 µg/mL 
(0.4%) remained after 24 hours (Figure 4A and B). This sug-
gests that the smaller CNHs were able to circulate longer, and 
their uptake by tissues was delayed. This behavior is common 
in the smaller nanoparticles which tend to reenter the blood 
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Figure 3 Whole-body sPecT/cT images of 111In-labeled s-cNhs and l-cNhs after intravenous injection in c57Bl/6 mice at 0.5, 3.5, 24, and 48 hours (h) postinjection.
Notes: The bright areas indicate the accumulation of 111In-labeled s-cNhs and l-cNhs. Images from left to right show whole-body, sagittal, frontal, and transverse views. 
The transverse cross-sectional images of spleen, liver, lung, kidney, and bladder are shown in the last columns.
Abbreviations: DTPa, diethylenetriaminepentaacetic acid; sPecT/cT, single-photon emission computed tomography/computed tomography; cNhs, carbon nanohorns; 
s-cNhs, small-sized cNhs; l-cNhs, large-sized cNhs.
stream.41 The larger [111In]DTPA-L-CNHs were taken up by 
the organs very rapidly at the first time points.
The S-CNH quantity in the liver (% ID/organ) was 
~6.1% at 1 hour and increased significantly after 4 hours 
to 37.4%, remaining high at 24 hours (41.5%). The S-CNH 
quantity in the spleen was ~8.2% and increased a little with 
time (Figure 4C). The larger [111In]DTPA-L-CNHs were 
taken up by the organs very rapidly at the first time point. 
The L-CNH quantity in the liver was 73.7% (% ID/organ) at 
1 hour, remaining unchanged at 4 and 24 hours (Figure 4D). 
The L-CNH quantity in the spleen was less than 5% at 1 hour, 
increasing a little with time. In other organs, quantities of 
S- and L-CNHs were very low, 2% (Figure 4).
A more accurate analysis of the data is given by mea-
suring the accumulation as percentage of the injected dose 
per gram of tissue (% ID/gram of tissue) (Figure 4E and F), 
to better express the affinity of CNH material for each tis-
sue. The preferential accumulation of CNHs in the liver and 
spleen was again evident. However, the accumulation of 
[111In]DTPA-S-CNHs in the spleen became more prominent, 
while the larger [111In]DTPA-L-CNHs expressed almost 
equal affinity to both organs. The size, sphericity, and 
deformability play a central role in accumulation of nano-
particles in tissues. Larger nanoparticles (150–200 nm) with 
spherical shapes tend to be trapped by the liver fenestra and 
recognized by Kupffer cells.42 Smaller particles (of ~100 nm 
in diameter) with elongated shapes may be sequestered by the 
spleen, unless being deformable enough to cross the spleen 
reticular network. The control sample [111In]DTPA showed 
rapid elimination from blood and only high kidney signals 
at early time points with no accumulation in other organs, 
with almost complete elimination after 24 hours (Figure S7, 
and Table 1).
cNh excretion
The values of % ID of S-CNHs or L-CNHs in the organs 
reported in Table 1 correspond to the quantities of materi-
als detected in the body at different time points. The total 
International Journal of Nanomedicine 2016:11 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
3323
radiolabeling whole-body images of carbon nanohorns in mice




      
%OR
RGF
RQF
ȝJ
P/

7LPHK

/LYHU6SOHH
Q
.LGQH
\V +HDU
W
/XQJ
V
0XVF
OH %RQH6WRP
DFK,QWHV
WLQH6NLQ





,'
SHU
RUJ
DQ





,'
SHU
JR
I
WLVV
XHV




      
%OR
RGF
RQF
ȝJ
P/

7LPHK






,'
SHU
RUJ
DQ





,'
SHU
JR
I
WLVV
XHV
$ %
& '
/LYHU
6SOHHQ
/LYHU
6SOHHQ
/LYHU
6SOHHQ
/LYHU 6SOHHQ
( )
JP/
JP/
/LYHU6SOHH
Q
.LGQH
\V +HDU
W
/XQJ
V
0XVF
OH %RQH6WRP
DFK,QWHV
WLQH6NLQ
/LYHU6SOHH
Q
.LGQH
\V +HDU
W
/XQJ
V
0XVF
OH %RQH6WRP
DFK,QWHV
WLQH6NLQ/LYHU6SOHH
Q
.LGQH
\V +HDU
W
/XQJ
V
0XVF
OH %RQH6WRP
DFK,QWHV
WLQH6NLQ
KKK
KKK
Figure 4 Quantities of [111In]-labeled s-cNhs and l-cNhs in mice obtained by gamma scintigraphy up to 24 hours postinjection.
Notes: (A, B) show concentrations detected in blood of 111In-labeled s-cNhs and l-cNhs, respectively. (C, D) results expressed by percentages of injected dose per 
whole organ (% ID/organ) for s-cNhs and l-cNhs, respectively. (E, F) Present the results expressed by percentages of injected dose per gram of organs (% ID/g) for 
s-cNhs and l-cNhs, respectively. Data are represented as mean ± standard error, n=4 mice per group.
Abbreviations: cNhs, carbon nanohorns; s-cNhs, small-sized cNhs; l-cNhs, large-sized cNhs; h, hour(s); conc, concentration.
Table 1 Percentage ID detected in major organs and blood by gamma quantification
Time (h) S-CNHs L-CNHs DTPA
Major  
organs (%)
Blood  
(%)
Total 
(%)
Major  
organs (%)
Blood  
(%)
Total 
(%)
Major  
organs (%)
Blood  
(%)
Total 
(%)
1 19.1 3.3 22.4 83.7 2.7 86.4 4.5 6.2 10.7
4 55.7 2.5 58.2 86.2 1.3 87.5 13.5 4.2 17.6
24 56.4 1.3 57.7 83.4 0.4 83.8 1.5 0.2 1.7
Abbreviations: h, hour(s); cNhs, carbon nanohorns; s-cNhs, small-sized cNhs; l-cNhs, large-sized cNhs; DTPa, diethylenetriaminepentaacetic acid.
amount of both S-CNHs and L-CNHs after 4 hours was 
58.2% and 87.5%, respectively. Liberation of 111In atoms 
from S-CNHs or L-CNHs was likely not happening because 
no decomplexation occurred in PBS and in serum at 37°C 
for 24 hours (Figure S3). Thus, it is inferred that a certain 
amount of S-CNHs or L-CNHs was excreted mainly in 
urine within the first few hours, followed by the small/
trace amount excretions in urine and feces continuing 
for 48 hours (Figures 3 and S7). The excreted quantity of 
S-CNHs was more than that of L-CNHs, detected by quan-
tities in urine, with 8% of S-CNHs excreted compared to 
only approximately 5% of the L-CNHs (Figure S7). This 
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may have been the case because the smaller sized S-CNHs 
could avoid phagocytotic uptake more effectively than the 
larger L-CNHs, as has been observed in a previous in vitro 
study.35 Also, small-sized nano-carbons were able to cross 
the glomerular filtration slits (40 nm)28 more comfortably 
than L-CNHs.
Urinary excretion was further confirmed by semi-
quantification of the SPECT bladder signal. S- and L-CNH 
quantities detected in the bladder after 1 hour were ~3.50 
and 2.16% of ID, respectively (Table S1). Both SPECT/CT 
and gamma scintigraphy data showed that overall small 
quantities of S-CNHs and L-CNHs (less than 10% ID) were 
detected in urine and feces at later time points of 24 and 
48 hours (Table S1 and Figure S7). Although the preferential 
accumulation of S-CNHs and L-CNHs in the liver and spleen 
has been reported in our previous histological observations,35 
the results obtained in this study by SPECT quantitatively 
confirmed that the biodistribution of nano-carbons in vivo is 
size-dependent. In addition, the excretion profile of CNHs func-
tionalized by [111In]DTPA was different from Gd
2
O
3
-labeled 
CNHs (100 nm aggregates) coated with DSPE-PEG 1,2-dis-
tearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(PEG)] 
(5 kDa),37 that were mainly excreted via the liver–bile duct–
duodenum route.37 The similar results from single-wall car-
bon nanotubes (SWNTs) and graphene oxide also indicated 
that DTPA-functionalized SWNTs27–29 or graphene oxide43 
exhibited faster clearance from the body than PEG-modified 
CNTs or graphene.44 Therefore, we think that the surface 
functionalization of CNHs with non-bulky functional groups, 
like DTPA, can lead to a different biodistribution and excre-
tion kinetic profile. This is effective in avoiding the uptake 
by phagocytes that may further facilitate excretion via both 
the urinary and liver–bile duct routes.
In addition, we did not find any signs of weakness, illness, 
or weight loss by visual inspection of the mouse and their 
organs after imaging.
Conclusion
We have studied the size-/shape-effect of CNHs on the biodis-
tribution and excretion profile by using two types of CNHs 
(S-CNH: 30 nm and L-CNH: 100 nm). These CNHs were 
covalently functionalized with [111In]DTPA and intravenously 
injected in mice. Their whole-body biodistribution profiles 
and excretion rates were studied by SPECT/CT and gamma 
scintigraphy. Both S-CNHs and L-CNHs accumulated 
mainly in the liver and spleen; however, S-CNHs exhibited 
higher affinity for the spleen. The larger, spherical L-CNHs 
accumulated in the liver and spleen to the same extent. A small 
amount of S-CNHs and L-CNHs was excreted within the first 
few hours after injection, followed by much slower excretion 
rates obtained after 48 hours. The excretion of S-CNHs was 
slightly faster than L-CNHs. Compared with the previous 
results for CNHs coated with phospholipid-PEG, the tissue 
distribution profile and kinetics of excretion determined for 
CNHs here were significantly different, most likely due to the 
differences in the material surface functionalization.
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Supplementary materials
Materials and methods
All reagents and solvents were purchased from different com-
mercial suppliers and used as received. 1H and 13C nuclear 
magnetic resonance (NMR) spectra were recorded on a 
Bruker 300 MHz instrument (Bruker Corporation, Billerica, 
MA, USA). The peak values were obtained as ppm (δ) and 
referenced to the solvent. The resonance multiplicity is indi-
cated as s (singlet), t (triplet), m (multiplet), and br (broad). 
Liquid chromatography–mass spectrometry analyses were 
performed on a Thermo Fisher Finnigan LCQ Advantage 
Max system (Thermo Fisher Scientific, Waltham, MA, 
USA). Thermogravimetric analysis was performed using 
a Thermogravimetric analysis 1 (Mettler Toledo, Schwer-
zenbach, Switzerland) apparatus from 100°C to 900°C with 
a ramp of 10°C min-1 under N
2
 (flow rate of 50 mL⋅min-1) 
and platinum pans.
The amino-diethylenetriaminepentaacetic acid deriva-
tive was synthesized from the t-Bu-protected diethylene-
triaminepentaacetic acid ligand reported in Marangon 
et al.1 The latter (665 mg) was stirred in trifluoroacetic acid 
(TFA) (8 mL) and deionized water (0.89 mL) for 17 hours. 
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Figure S1 Preparation of amino-DTPa.
Abbreviations: DTPa, diethylenetriaminepentaacetic acid; h, hours.
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Figure S2 Radiolabeling efficiency of [111In]DTPa-s-cNhs and [111In]DTPa-l-cNhs compared to control [111In]DTPa, measured directly after radiolabeling reaction.
Abbreviations: DTPa, diethylenetriaminepentaacetic acid; cNhs, carbon nanohorns; s-cNhs, small-sized cNhs; l-cNhs, large-sized cNhs.
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Figure S3 Tlc papers showing the radiolabeling stability of [111In]DTPa-s-cNhs and [111In]DTPa-l-cNhs in mouse serum (left column) and PBs (right column) over 
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Abbreviations: Tlc, thin-layer chromatography; DTPa, diethylenetriaminepentaacetic acid; cNhs, carbon nanohorns; s-cNhs, small-sized cNhs; l-cNhs, large-sized 
cNhs; PBs, phosphate-buffered saline.






U
DGLR
DFLY
LW\D
W
DSS
OLFD
WLRQ
SRL
QW
5DGLRODEHOLQJVWDELOLW\LQVHUXP






5DGLRODEHOLQJVWDELOLW\LQ3%6
KKK KKK
>,Q@'73$6&1+ >,Q@'73$/&1+
Figure S4 radiolabeling stability of [111In]DTPa-s-cNhs and [111In]DTPa-l-cNhs in mouse serum (left) and PBs (right) over 24 hours (h).
Abbreviations: DTPa, diethylenetriaminepentaacetic acid; cNhs, carbon nanohorns; s-cNhs, small-sized cNhs; l-cNhs, large-sized cNhs; PBs, phosphate-buffered 
saline.
International Journal of Nanomedicine 2016:11submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
3328
Zhang et al
W 
K
W 
K
W 
K
/XQJ
/LYHU
.LGQH\
%ODGGHU
6SOHHQ
/XQJ
/LYHU
.LGQH\
%ODGGHU
6SOHHQ
/XQJ
/LYHU
.LGQH\
%ODGGHU
6SOHHQ
Figure S5 sPecT/cT images of [111In]DTPa control injected mouse at 0.5, 3.5, and 24 hours (h) postinjection.
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Figure S6 Quantities of [111In]DTPa control injected intravenously in mice detected by gamma scintigraphy up to 24 hours (h) postinjection.
Notes: (A) Detected in whole blood by concentration (µg/ml). (B) Percentage ID per whole organ, and (C) expressed by % ID per gram of tissues. Data are represented 
as mean ± standard error, n=4 mice per group.
Abbreviations: DTPa, diethylenetriaminepentaacetic acid; conc, concentration.
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Then, the reaction mixture was evaporated under vacuum to 
give a beige solid in a quantitative yield. 1H NMR (300 MHz, 
dimethyl sulfoxide-d
6
 as a TFA salt, the signal of TFA was 
not included) δ=1.42–1.64 (m, 4 H), 1.74–1.92 (m, 2 H), 
2.72–2.85 (m, 2 H), 2.98–3.15 (m, 4 H), 3.25–3.40 (m, 4 
H), 3.60 (s, 8 H), 4.45 ppm (t, J=6.5 Hz, 1 H), 7.84 (br s, 
3 H). 13C NMR (75 MHz, dimethyl sulfoxide-d
6
 as a TFA 
salt, the signal of TFA was not included) δ=23.1, 26.3, 
26.9, 38.3, 49.9, 50.1, 54.1, 63.7, 170.5, 172.2 ppm. Liquid 
chromatography–mass spectrometry [molecular weight 
(ammonium) 465]: m/z 465 [M]+.
Reference
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Table S1 Percentage ID detected in bladder by single-photon 
emission computed tomography/computed tomography semi-
quantification
Time (h) DTPA (%) S-CNHs (%) L-CNHs (%)
0.5 3.9 3.5 2.2
3.5 1.3 0.2 1.0
24 0.1 0.3 0.4
48 0.0 0.5 0.2
Total 5.3 4.4 3.8
Abbreviations: h, hour(s); DTPa, diethylenetriaminepentaacetic acid; cNhs, carbon 
nanohorns; s-cNhs, small-sized cNhs; l-cNhs, large-sized cNhs.
